Why does the same carcinogen trigger tumors in some people but leave others untouched? An international research team believes they have found a crucial answer: inherited genetics acts as a master switch, determining not just cancer risk but also how tumors evolve once they begin.
The discovery, published in Nature, comes from a carefully controlled mouse study that isolated genetic influence from the chaos of human life. Researchers bred four mouse strains with different genetic backgrounds and exposed them all to the same liver carcinogen at the same age, then watched what happened.
The results were striking. Although nearly every tumor activated the same cancer-promoting pathway known as MAPK, the specific mutations that appeared and the evolutionary trajectories the cancers followed varied dramatically based on each mouse's inherited genetics. Some genetic backgrounds even showed a tendency toward whole-genome duplication, a catastrophic copying of all chromosomes.
"Cancer does not arise entirely by chance," said Professor Duncan Odom of Germany's DKFZ, who led the research. "Although tumors often reach the same biological endpoint, the path to that endpoint is determined by an individual's genetic background."
The work resolves a long-standing puzzle in cancer science. Epidemiologists have known for decades that identical environmental exposures produce wildly different outcomes: most smokers never develop lung cancer, while some nonsmokers do. But separating inherited genetics from the tangle of lifestyle differences, environmental variation, and exposure history has proven nearly impossible in human studies.
The research team from Cambridge, Edinburgh, and institutions across Europe and the US took a different approach. They used nearly 600 sequenced tumors from their mouse models and traced the genetic history of each one back to its origin. By keeping everything constant except genetic background, they could see its influence with clarity.
The implications ripple far beyond basic science. Dr. Sarah Aitken, first author of the study and now at Yale, said the findings could fundamentally reshape how medicine approaches cancer prevention and treatment. "If genetic background influences both cancer risk and the evolutionary trajectory of tumors, future cancer prevention and screening strategies will need to take into account inherited genetics and population diversity," she said.
The team also found evidence that inherited genetics shapes how cells respond to DNA damage itself, suggesting that cancer drugs targeting specific mutations may work differently depending on a patient's genetic makeup. This strengthens the case for personalized medicine, where treatment and screening decisions account for individual genetic variation rather than treating all patients identically.
Cancer Research UK's Sam Godfrey cautioned that mouse models do not automatically translate to humans. "We still need to see more research before we can understand what this means in humans, but this finding could change our understanding of how cancer starts, and lead to more powerful and precise ways of tackling cancer."
For now, the work opens a new frontier: understanding cancer not as a simple accumulation of random mutations, but as an evolutionary process shaped by the genetic terrain in which those mutations take root.
Author Jessica Williams: "This study flips the script on how we think about cancer risk, moving the spotlight from bad luck to bad genetic combinations with bad exposures."
Comments